NeuroSense sets 1-for-20 reverse share split

NeuroSense Therapeutics is implementing a 1-for-20 reverse share split effective with Nasdaq trading on September 14, 2026.

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. (NRSN) approved a 1-for-20 reverse share split of its ordinary shares, consolidating every twenty existing shares into one new share. Trading on the Nasdaq Capital Market on a reverse-split-adjusted basis will begin on September 14, 2026.

The reverse split will reduce issued and outstanding ordinary shares from 37,938,036 to 1,896,902, while the authorized share capital will remain unchanged. Fractional shares will not be issued and will instead be rounded up to the nearest whole share, and outstanding warrants and options will be adjusted proportionately.

Key Figures

Reverse split ratio: 1-for-20 Pre-split issued and outstanding shares: 37,938,036 shares Post-split issued and outstanding shares: 1,896,902 shares +2 more

5 metrics

Reverse split ratio 1-for-20 Each twenty ordinary shares consolidated into one ordinary share

Pre-split issued and outstanding shares 37,938,036 shares Ordinary shares before implementation of the reverse split

Post-split issued and outstanding shares 1,896,902 shares Ordinary shares after implementation of the reverse split, subject to fractional adjustments

Effective Nasdaq trading date September 14, 2026 First trading date on Nasdaq Capital Market after implementation of the reverse split

New CUSIP M74240207 CUSIP for NeuroSense ordinary shares after the reverse share split

Key Terms

reverse share split, Nasdaq Capital Market, authorized share capital, CUSIP

4 terms

reverse share split financial

"announcing that it will effect a reverse share split of the Company’s ordinary shares"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

Nasdaq Capital Market market

"will begin trading on the Nasdaq Capital Market after implementation of the reverse split"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

authorized share capital financial

"Following the implementation of the reverse split, the Company’s authorized share capital will remain unchanged"

The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.

CUSIP financial

"The new CUSIP number for the ordinary shares will be M74240207"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

Stock Split

1-for-20 reverse split · Effective September 14, 2026

Split Ratio 1-for-20 reverse split

Effective Date September 14, 2026

Shares Before Split 37,938,036

Shares After Split 1,896,902

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse share split did NeuroSense Therapeutics (NRSN) announce?

NeuroSense Therapeutics announced a 1-for-20 reverse share split of its ordinary shares, meaning each block of twenty existing ordinary shares will be consolidated into one new ordinary share, with no change to the company’s authorized share capital.

When will NRSN begin trading on a reverse-split-adjusted basis?

NeuroSense’s ordinary shares will begin trading on the Nasdaq Capital Market on a reverse-split-adjusted basis on September 14, 2026, which is described as the first trading date after implementation of the reverse share split.

How will the NRSN reverse split change the number of outstanding shares?

The reverse split will reduce NeuroSense’s issued and outstanding ordinary shares from 37,938,036 shares to 1,896,902 shares, subject to adjustments for the treatment of fractional shares as described in the announcement.

How will NeuroSense (NRSN) handle fractional shares in the reverse split?

No fractional ordinary shares will be issued. Instead, all fractional shares will be rounded up to the nearest whole ordinary share, so each shareholder will hold only whole shares after the reverse share split.

What happens to NRSN warrants and options after the reverse share split?

NeuroSense states that a proportionate adjustment will be made to the per share exercise price and the number of ordinary shares issuable upon exercise of all outstanding warrants and options, aligning those instruments with the 1-for-20 reverse share split.

What is the new CUSIP for NeuroSense (NRSN) ordinary shares after the split?

After the reverse share split, the ordinary shares of NeuroSense Therapeutics will trade under the new CUSIP M74240207, replacing the prior CUSIP for the company’s ordinary shares.

How is this reverse split filing used in NeuroSense’s existing registration statements?

The report is incorporated by reference into NeuroSense’s Form S-8 registration statements (File Nos. 333-262480 and 333-289658) and Form F-3 registration statements (File Nos. 333-269306, 333-283656, 333-284051, 333-291122 and 333-293060).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:31 PM EDT Accepted by SEC EDGAR 09/09/2026 - 04:30 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2026

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

2 Ha-Tidhar Street

Ra’anana 4366504, Israel

+972-58-7531153

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

NeuroSense Therapeutics Ltd. (the “Company”) is announcing that it will effect a reverse share split of the Company’s ordinary shares at the ratio of 1-for-20, such that each twenty (20) ordinary shares, no par value, shall be consolidated into one (1) ordinary share, no par value. The first date when the Company’s ordinary shares will begin trading on the Nasdaq Capital Market after implementation of the reverse split will be Monday, September 14, 2026.

Following the implementation of the reverse split, the Company’s authorized share capital will remain unchanged. The reverse split will adjust the number of issued and outstanding ordinary shares of the Company from 37,938,036 ordinary shares to 1,896,902 ordinary shares (subject to any further adjustments based on the treatment of fractional shares).

No fractional ordinary shares will be issued as a result of the reverse split. All fractional ordinary shares will be rounded up to the nearest whole ordinary share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding warrants and options entitling the holders to purchase ordinary shares. The new CUSIP number for the ordinary shares will be M74240207.

This Report on Form 6-K is hereby incorporated by reference into registrant’s Registration Statements on Form S-8 (File No. 333-262480 and 333-289658) and Form F-3 (File No. 333-269306, 333-283656, 333-284051, 333-291122 and 333-293060), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: September 9, 2026	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2